Prestige Consumer Healthcare Inc
F:PBV
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
EV/OCF
Enterprise Value to Operating Cash Flow (EV/OCF) ratio compares a company`s total enterprise value to its operating cash flow. It shows how much investors are paying for each dollar of the company`s operating cash flow, including both equity and debt.
Enterprise Value to Operating Cash Flow (EV/OCF) ratio compares a company`s total enterprise value to its operating cash flow. It shows how much investors are paying for each dollar of the company`s operating cash flow, including both equity and debt.
Valuation Scenarios
If EV/OCF returns to its 3-Year Average (18.5), the stock would be worth €67.53 (37% upside from current price).
| Scenario | EV/OCF Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 13.5 | €49.2 |
0%
|
| 3-Year Average | 18.5 | €67.53 |
+37%
|
| 5-Year Average | 17.7 | €64.66 |
+31%
|
| Industry Average | 14.4 | €52.54 |
+7%
|
| Country Average | 16.7 | €60.86 |
+24%
|
Forward EV/OCF
Today’s price vs future operating cash flow
Peer Comparison
| Market Cap | EV/OCF | P/E | ||||
|---|---|---|---|---|---|---|
| US |
|
Prestige Consumer Healthcare Inc
F:PBV
|
2.7B EUR | 13.5 | 14.7 | |
| US |
|
Eli Lilly and Co
NYSE:LLY
|
853.2B USD | 52.7 | 41.3 | |
| US |
|
Johnson & Johnson
NYSE:JNJ
|
544.6B USD | 23.3 | 25.9 | |
| CH |
|
Roche Holding AG
SIX:ROG
|
248.4B CHF | 14.9 | 19.6 | |
| UK |
|
AstraZeneca PLC
LSE:AZN
|
225.8B GBP | 22 | 29.3 | |
| CH |
|
Novartis AG
SIX:NOVN
|
222.8B CHF | 15.5 | 20 | |
| US |
|
Merck & Co Inc
NYSE:MRK
|
278.5B USD | 18.9 | 15.3 | |
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
244.4B USD | 936 | -83.6 | |
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.1T DKK | 10.1 | 10.8 | |
| US |
|
Pfizer Inc
NYSE:PFE
|
155.3B USD | 17.4 | 20 | |
| US |
|
Bristol-Myers Squibb Co
NYSE:BMY
|
119.6B USD | 10.8 | 17 |
Market Distribution
| Min | 0 |
| 30th Percentile | 11.7 |
| Median | 16.7 |
| 70th Percentile | 23.6 |
| Max | 3 178 983.5 |
Other Multiples
Prestige Consumer Healthcare Inc
Glance View
Prestige Consumer Healthcare Inc. has carved out its niche in the competitive realm of over-the-counter healthcare products with a distinct flair. Born out of a series of insightful acquisitions and strategic brand cultivations, the company has crafted a portfolio that caters to a broad spectrum of consumer health needs. It offers an expansive range of products, from well-known pain relievers and eye care items to gastrointestinal treatments and women’s health solutions. The cornerstone of Prestige's success lies in its acute understanding of consumer demand and its agile response to market trends. By developing and acquiring brands that are established household names—such as Clear Eyes, Chloraseptic, and Dramamine—the firm has effectively secured a reliable revenue stream. Each brand, while under the corporate umbrella of Prestige, thrives on its ability to resonate with consumers who seek trustworthy, easily accessible remedies. Central to Prestige’s business model is its adeptness at maintaining and enhancing brand equity. Through a blend of focused marketing strategies and disciplined cost management, the company ensures consistent visibility and availability of its products across key retail channels, including mass merchandisers, drug retailers, and e-commerce. Prestige's skillful navigation of the marketplace allows it to capitalize on scale economies and maintain healthy margins. Each product in its portfolio is not only a testament to its commitment to quality and efficacy but also to its strategic foresight in addressing the ever-evolving healthcare challenges faced by consumers. In essence, Prestige Consumer Healthcare Inc. thrives by blending astute brand management with a keen focus on consumer health trends, ensuring its position as a formidable player in the healthcare industry.